Open AccessPeptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors
Author(s) -
Mohammadali Hamiditabar,
Ali Muzammil,
Joseph Roys,
Edward M. Wolin,
Thomas M. O'Dorisio,
David Ranganathan,
Izabela Tworowska,
Jonathan Strosberg,
Ebrahim S. Delpassand
Publication year - 2017
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000001629
Subject(s) - radionuclide therapy , medicine , neuroendocrine tumors , somatostatin receptor , somatostatin , adverse effect , octreotide , peptide receptor , response evaluation criteria in solid tumors , oncology , gastroenterology , chemotherapy , phases of clinical research , receptor
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide lutetium Lu, we now present further results of Lu DOTATATE therapy in managing NETs and other somatostatin receptor-expressing tumors in a larger and more diverse patient group.